{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:32:39Z","timestamp":1793338359525,"version":"4.5.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec id=\"ab-hoi230050-4\"><jats:title>Importance<\/jats:title><jats:p>Lipoprotein(a) (Lp[a]) concentrations are a highly heritable and potential causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Recent consensus statements by the European Atherosclerosis Society and American Heart Association recommend screening of relatives of individuals with high Lp(a) concentrations, but the expected yield of this approach has not been quantified in large populations.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230050-5\"><jats:title>Objective<\/jats:title><jats:p>To measure the prevalence of high Lp(a) concentrations among first- and second-degree relatives of individuals with high Lp(a) concentrations compared with unrelated participants.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230050-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>In this cross-sectional analysis, pairs of first-degree (n\u2009=\u200919\u202f899) and second-degree (n\u2009=\u20099715) relatives with measured Lp(a) levels from the UK Biobank study and random pairs of unrelated individuals (n\u2009=\u2009184\u202f764) were compared. Data for this study were collected from March 2006 to August 2010 and analyzed from December 2021 to August 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230050-7\"><jats:title>Exposure<\/jats:title><jats:p>Serum Lp(a) levels, with a high Lp(a) level defined as at least 125 nmol\/L.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230050-8\"><jats:title>Main Outcome and Measure<\/jats:title><jats:p>Concordance of clinically relevant high Lp(a) levels in first- and second-degree relatives of index participants with high Lp(a) levels.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230050-9\"><jats:title>Results<\/jats:title><jats:p>A total of 52 418 participants were included in the analysis (mean [SD] age, 57.3\u2009[8.0] years; 29 825 [56.9%] women). Levels of Lp(a) were correlated among pairs of first-degree (Spearman \u03c1\u2009=\u20090.45;<jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and second-degree (Spearman \u03c1\u2009=\u20090.22;<jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) relatives. A total of 1607 of 3420 (47.0% [95% CI, 45.3%-48.7%]) first-degree and 514 of 1614 (31.8% [95% CI, 29.6%-34.2%]) second-degree relatives of index participants with high Lp(a) levels also had elevated concentrations compared with 4974 of 30\u202f258 (16.4% [95% CI, 16.0%-16.9%]) pairs of unrelated individuals. The concordance in high Lp(a) levels was generally consistent among subgroups (eg, those with prior ASCVD, postmenopausal women, and statin users). The odds ratios for relatives to have high Lp(a) levels if their index relative had a high Lp(a) level compared with those whose index relatives did not have high Lp(a) levels were 7.4 (95% CI, 6.8-8.1) for first-degree relatives and 3.0 (95% CI, 2.7-3.4) for second-degree relatives.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230050-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings of this cross-sectional study suggest that the yield of cascade screening of first-degree relatives of individuals with high Lp(a) levels is over 40%. These findings support recent recommendations to use this approach to identify additional individuals at ASCVD risk based on Lp(a) concentrations.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.3548","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T15:09:25Z","timestamp":1697036965000},"page":"1111","source":"Crossref","is-referenced-by-count":32,"title":["Concordance of a High Lipoprotein(a) Concentration Among Relatives"],"prefix":"10.1001","volume":"8","author":[{"given":"Laurens F.","family":"Reeskamp","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycho R.","family":"Tromp","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddh P.","family":"Patel","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts"},{"name":"Division of Cardiology and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Trinder","sequence":"additional","affiliation":[{"name":"Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Haidermota","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Massachusetts General Hospital, Boston"},{"name":"Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Novo Nordisk, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S. G.","family":"Stroes","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts"},{"name":"Division of Cardiology and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit V.","family":"Khera","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts"},{"name":"Verve Therapeutics, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"hoi230050r1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis.","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hoi230050r4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk.","volume":"79","author":"Trinder","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6562","key":"hoi230050r5","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abg8289","article-title":"Protein-coding repeat polymorphisms strongly shape diverse human phenotypes.","volume":"373","author":"Mukamel","year":"2021","journal-title":"Science"},{"issue":"1","key":"hoi230050r6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"issue":"39","key":"hoi230050r7","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi230050r8","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association.","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"hoi230050r9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia.","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"hoi230050r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2022.100343","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a).","volume":"10","author":"Chakraborty","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"25","key":"hoi230050r11","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"7726","key":"hoi230050r12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data.","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"22","key":"hoi230050r13","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1093\/bioinformatics\/btq559","article-title":"Robust relationship inference in genome-wide association studies.","volume":"26","author":"Manichaikul","year":"2010","journal-title":"Bioinformatics"},{"issue":"2","key":"hoi230050r14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.120.003262","article-title":"Concordance of a high polygenic score among relatives: implications for genetic counseling and cascade screening.","volume":"14","author":"Reid","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"hoi230050r15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank.","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"hoi230050r16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/ng.3643","article-title":"A reference panel of 64,976 haplotypes for genotype imputation.","volume":"48","author":"McCarthy","year":"2016","journal-title":"Nat Genet"},{"issue":"7571","key":"hoi230050r17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nature14962","article-title":"The UK10K project identifies rare variants in health and disease.","volume":"526","author":"Walter","year":"2015","journal-title":"Nature"},{"issue":"7571","key":"hoi230050r18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation.","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"26","key":"hoi230050r19","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease.","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"hoi230050r20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses.","volume":"367","author":"St\u00fcrzebecher","year":"2023","journal-title":"Atherosclerosis"},{"issue":"11","key":"hoi230050r21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.119.002723","article-title":"New case detection by cascade testing in familial hypercholesterolemia: a systematic review of the literature.","volume":"12","author":"Lee","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"hoi230050r22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2022.02.013","article-title":"How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?","volume":"349","author":"Catapano","year":"2022","journal-title":"Atherosclerosis"},{"issue":"14","key":"hoi230050r23","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1093\/eurjpc\/zwac124","article-title":"Lipoprotein(a) testing in clinical practice: real-life data from a large healthcare provider.","volume":"29","author":"Zafrir","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"hoi230050r24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic.","volume":"349","author":"De Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"hoi230050r2","unstructured":"Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp[a]HORIZON). ClinicalTrials.gov Identifier: NCT04023552. Updated August 8, 2023. Accessed July 4, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04023552"},{"key":"hoi230050r3","unstructured":"Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN[a])\u2014Outcomes Trial. ClinicalTrials.gov Identifier: NCT05581303. Updated July 27, 2023. Accessed July 4, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05581303"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2810102\/jamacardiology_reeskamp_2023_oi_230050_1702400223.64286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:31:06Z","timestamp":1730305866000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2810102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.3548","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}